Please assess the completion status of the following clinical trial:

Trial Title: Preferred Treatment of Type 1.5 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at onset of diabetes - 35-69 years old.~* No history of ketonuria or ketoacidosis.~* Not requiring insulin to achieve glycemic control.~* Not receiving more than two oral hypoglycemic agents.~* Not taking a thiazolidinedione agent.~* HbA1c in established patients (on an oral hypoglycemia agent for over 4 months) of greater than 6% and under 10%.~* Fasting c-peptide greater than or equal to 0.8 ng/ml.~* Women must be either post-menopausal or on adequate birth control (i.e. oral contraceptives, tubal ligation, hysterectomy, condoms, or diaphragm) or use abstinence.~Exclusion Criteria:~* Patients with history of chronic pancreatitis or other secondary causes of diabetes.~* Patients receiving systemic corticosteroids.~* Patients with severe systemic illness (e.g. recent MI, CHF or cerebral vascular disease).~* Creatinine greater than 1.4 or liver enzymes greater than 2 times the upper limits of normal.~* Not able to adhere to the protocol.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- rosiglitazone (Type: ACTIVE_COMPARATOR): Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The rosiglitazone treatment group commenced therapy with 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved.
- glyburide (Type: ACTIVE_COMPARATOR): Glyburide is a sulfonylurea. Glyburide therapy was initiated with 2.5 mg in the morning or the patient was maintained on the dose they had been receiving prior to starting the study. This starting dose was raised by 2.5 in the evening and further up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control.

Based on this trial design, predict the completion outcome and termination type (if applicable).